Literature DB >> 24372628

Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A.

J G van der Bom1, S C Gouw, F R Rosendaal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24372628     DOI： 10.1111/hae.12342

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  4 in total

1.  Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A.

Authors:  Erik Berntorp; Alfonso Iorio
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

2.  Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

Authors:  Peter W Collins; Benedict P Palmer; Elizabeth A Chalmers; Daniel P Hart; Ri Liesner; Savita Rangarajan; Katherine Talks; Michael Williams; Charles R M Hay
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

3.  Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Authors:  Thierry Calvez; Hervé Chambost; Roseline d'Oiron; Vincent Dalibard; Virginie Demiguel; Alexandra Doncarli; Yves Gruel; Yoann Huguenin; Patrice Lutz; Chantal Rothschild; Christine Vinciguerra; Jenny Goudemand
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941

4.  Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.

Authors:  J F Healey; E T Parker; P Lollar
Journal:  J Thromb Haemost       Date:  2018-01-11       Impact factor: 5.824
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.